TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33651116
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 37 MBq (± 10%)
Study: 33651243
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion with conversation
Study: 33651243
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion in a quiet environment
Study: 33653216
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with fludarabine, cyclophosphamide, and ofatumumab; consolidation with 4 doses of ofatumumab for MRD+ patients
Study: 33653216
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including induction and consolidation)
Study: 33653294
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice treatment according to the center
Study: 33653374
Drug: CPS-mandated treatment
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPS-mandated treatment
Study: 33654090
Drug: BBV152 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBV152 vaccine candidate (three different formulations) administered at 0 and 14 days
Study: 33655971
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injection (ILESI)
Study: 33656739
Drug: Peficitinib 50
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 50 or 100 mg/day (with dose adjustments allowed)
Study: 33657594
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment following French guidelines, specifically amoxicillin.
Study: 33658052
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) 0.10 mg/kg, 0.15 mg/kg, and 0.20 mg/kg IV infusions
Study: 33659204
Drug: Apatinib 425
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 425 mg once daily
Study: 33659261
Drug: Guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided therapy
Study: 33660194
Drug: LY3023414 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023414 200 mg BID
Study: 33661190
Drug: Ibrutinib, 840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib, 840 mg PO QD
Study: 33662447
Drug: Risk-stratified treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-stratified treatments based on disease biomarkers
Study: 33663941
Drug: Neratinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib at 240 mg daily in 28-day cycles
Study: 33664128
Drug: hu3S193, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu3S193, 30 mg/m² intravenous infusions
Study: 33669715
Drug: Music-based rhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-based rhythmic auditory stimulation (RAS) in combination with conventional physiotherapy
Study: 33671555
Drug: IO103 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO103 vaccine with Montanide adjuvant
Study: 33671691
Drug: Probiotic product
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic product (1 capsule/day)
Study: 33673868
Drug: Wearable patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable patch for remote monitoring of vital signs (heart rate, respiratory rate, temperature) during stay in hotel quarantine.
Study: 33674856
Drug: Facebook group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facebook group intervention to reduce barriers to evidence-based smoking cessation treatment
Study: 33675179
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin 2.4 mg/kg
Study: 33675179
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin 2.7 mg/kg
Study: 33675179
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin (both doses)
Study: 33675184
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen, including two cycles of paclitaxel and ifosfamide followed by three cycles of HD carboplatin plus etoposide, with carboplatin dose adapted based on clearance to reach a target AUC of 24 mg.min/mL per cycle.
Study: 33675184
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen.
Study: 33675184
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with TI-CE regimen for high- and very high-risk patients.
Study: 33676628
Drug: Pirtobrutinib 200
Normalized name: PIRTOBRUTINIB 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib 200 mg daily
Study: 33677480
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (anti-PD-1 and anti-CTLA-4) combination therapy
Study: 33677504
Drug: Increased mineralocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased mineralocorticoid dose during childhood
Study: 33677553
Drug: Chemical renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemical renal denervation (RDN) using Peregrine System Infusion Catheter, Ablative Solutions (n = 4; 2F:2M)
Study: 33677615
Drug: UGN-101 (mitomycin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-101 (mitomycin-containing reverse thermal gel)
Study: 33679478
Drug: Internet-Administered Emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Administered Emotional Awareness and Expression Therapy
Study: 33681244
Drug: Improved use
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved use of chewing gum during capsule endoscopy
Study: 33681273
Drug: Long-term treatments
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatments (three different types)
Study: 33681747
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg nightly for one year)
Study: 33682447
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin combined with novel agents (GSK3174998, feladilimab, nirogacestat, dostarlimab)
Study: 33682447
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin monotherapy
Study: 33682527
Drug: Opioid receptor
Normalized name: Opioid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid receptor antagonists, specific dosage and duration not mentioned
Study: 39647797
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg subcutaneously once daily for 10 days
Study: 37364223
Drug: nab-paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel monotherapy
Study: 33683582
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy (n = 82, ESC-CONT)
Study: 33683582
Drug: Adjunctive Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive Aripiprazole (n = 88, ESC-ARI)
Study: 33683917
Drug: Umbralisib 800
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal
Study: 33683917
Drug: Umbralisib 800
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umbralisib 800 mg orally once daily
Study: 33684160
Drug: GSK1070806 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 (3 mg/kg intravenous)
Study: 33684377
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG) at 0.1 g/kg/week for up to 6 months
Study: 33685522
Drug: MANTRa therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MANTRa therapy (24 to 34 individual weekly sessions)
Study: 33685522
Drug: TAU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment as usual, weekly sessions)
Study: 33685522
Drug: MANTRa therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MANTRa therapy
Study: 33686413
Drug: Individualised luteal
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised luteal phase support (iLPS) through daily subcutaneous P4 injections (Psc) started the day prior to FET.
Study: 33686452
Drug: Crenigacestat (LY3039478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (LY3039478) in combination with LY3023414
Study: 33686452
Drug: Crenigacestat (LY3039478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (LY3039478) in combination with abemaciclib
Study: 33686452
Drug: Crenigacestat (LY3039478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (LY3039478) in combination with taladegib
Study: 33686631
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day for mild renal impairment, 0.75 mg/day for moderate renal impairment, 0.5 mg/day for severe renal impairment)
Study: 33686631
Drug: Talazoparib (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (0.5 mg/day for severe renal impairment)
Study: 33687163
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg per day)
Study: 34261767
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (NSPT)
Study: 33687667
Drug: Automated method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for ECoG electrodes recognition.
Study: 33687667
Drug: Automated method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for simultaneous recognition of depth and ECoG electrodes.
Study: 33687687
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (RCI; Acthar) 80 U subcutaneously every other day through week 4, then twice weekly through week 24
Study: 33687687
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (RCI; Acthar)
Study: 33688022
Drug: Galunisertib 150
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib 150 mg two times per day co-administered with durvalumab 1500 mg Q4W
Study: 33688228
Drug: Orlistat (120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120mg three times daily) and Phentermine (37.5mg once daily)
Study: 33688228
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily) and Phentermine (37.5mg once daily)
Study: 33688834
Drug: Tri/tetracyclic antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri/tetracyclic antidepressants + SGA
Study: 33688834
Drug: Psychotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy alone (without medication)
Study: 33691262
Drug: GLS-010 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-010 at a dose of 240 mg Q2W
Study: 33691262
Drug: GLS-010 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-010 at doses of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W
Study: 33691480
Drug: Evinacumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab, dosage and duration not specified
Study: 33691765
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (thromboprophylactic doses of LMWH or UFH)
Study: 33692132
Drug: siBcl2L12-SNAs (NU-0129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: siBcl2L12-SNAs (NU-0129) administered intravenously at a dose corresponding to 1/50th of the no-observed-adverse-event level
Study: 33692132
Drug: siBcl2L12-SNAs (NU-0129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: siBcl2L12-SNAs (NU-0129) administered intravenously
Study: 33692727
Drug: Communication skills
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication skills training for radiographers; details on dosage and duration not available
Study: 33693009
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard oxygen therapy)
Study: 33693776
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg gliclazide
Study: 33693813
Drug: No Vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Vitamin D supplements
Study: 33693943
Drug: Anti-HIV antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-HIV antibodies
Study: 33694257
Drug: Lenalidomide (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (starting dose 2 mg/kg/day on days 1-21 of each 28-day cycle for a maximum of 12 cycles)
Study: 33704071
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin 150 mg
Study: 33704071
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin 300 mg
Study: 33705565
Drug: Oxytocin solution
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin solution
Study: 33706339
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by misoprostol 800 micrograms buccally
Study: 33707233
Drug: Intratumoral tilsotolimod
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral tilsotolimod (8 mg) with systemic ipilimumab
Study: 33708474
Drug: Inappropriate low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate low doses of NOACs
Study: 33708484
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly injections
Study: 33708780
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (LD-DAC, 5 mg/m²)
Study: 33708965
Drug: Docetaxel continuation
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel continuation maintenance (DCM) therapy
Study: 33710399
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no atypical antipsychotic during pregnancy)
Study: 33710523
Drug: First/second-generation EGFR-tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: First/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs)
Study: 33710523
Drug: Other systemic
Normalized name: Other systemic hemostatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other systemic treatments
Study: 33710523
Drug: Subsequent systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent systemic treatment after progression on 1G/2G EGFR-TKIs
Study: 33710976
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (3-6 mg/kg, single oral or intravenous dose)
Study: 33711074
Drug: TAK-003 (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (tetravalent live attenuated dengue vaccine)
Study: 33711699
Drug: Granulocyte-Colony Stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-Colony Stimulating Factors (G-CSF)
Study: 33712086
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 6.25 mg/kg oral capsules twice daily for 6 weeks, potentially increasing to 12.5 mg/kg twice daily for another 6 weeks if pain is not adequately controlled
Study: 33712849
Drug: Venetoclax 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 400 mg/day (3-day ramp up in cycle 1) plus azacitidine 75 mg/m2 on days 1-7 per 28-day cycle
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 50 mg
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 100 mg
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 200 mg
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 400 mg
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 600 mg
Study: 33713216
Drug: HLX07 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 at 800 mg
Study: 33713742
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 30 mg/m² with adjuvant radiation therapy
Study: 33713742
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 10 mg/m²
Study: 33715620
Drug: eGDR tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGDR tertile T3 (≤ 4.14 mg/kg/min, highest IR)
Study: 33715620
Drug: eGDR tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGDR tertile T1 (≥ 5.35 mg/kg/min)
Study: 33716499
Drug: Various anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various anesthetic agents
Study: 33716499
Drug: Inhalational agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational agents
Study: 33716817
Drug: Pharmacological treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment, specific details not available.
Study: 33716948
Drug: Arm-Hand Boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm-Hand Boost Therapy during inpatient stroke rehabilitation
Study: 33717057
Drug: BCMA-directed Chimeric
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-directed Chimeric Antigen Receptor T cells (CART) therapy
Study: 33718228
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccination with peptide CALRLong36, 15 vaccines administered
Study: 33719441
Drug: GLPG1972/S201086, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor, dosage and duration not specified.
Study: 33719441
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified, but implied as untreated or standard treatment.
Study: 33719721
Drug: PH FDC
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH FDC SC (subcutaneous injection)
Study: 33719728
Drug: Nonmotor experiences
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmotor experiences of daily living
Study: 33720032
Drug: eVisits for
Approvals — FDA: no, EMA: no, PMDA: no
Description: eVisits for sore throat (guideline-recommended antibiotics)
Study: 33720032
Drug: eVisits for
Approvals — FDA: no, EMA: no, PMDA: no
Description: eVisits for respiratory symptoms (guideline-recommended antibiotics)
Study: 33720032
Drug: eVisits for
Approvals — FDA: no, EMA: no, PMDA: no
Description: eVisits for dysuria (guideline-recommended antibiotics)
Study: 33720336
Drug: Lisocabtagene maraleucel
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisocabtagene maraleucel (CAR T-cell therapy)
Study: 33720337
Drug: Rituximab-based therapies
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-based therapies (including R-Dox) with maintenance AZT/VGC or interferon
Study: 33720337
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments administered at investigator discretion
Study: 33720337
Drug: Concurrent diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent diagnosis of PEL
Study: 33720424
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks for 3 cycles
Study: 33720749
Drug: Bundled Acupuncture
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bundled Acupuncture and Yoga Therapy
Study: 33721289
Drug: Anticholinergic Drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic Drug Scale (ADS)
Study: 33721837
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 1000 IU single dose
Study: 33722701
Drug: Chemotherapy including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy including steroids (dexamethasone)